X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33901) 33901
Newspaper Article (382) 382
Magazine Article (380) 380
Newsletter (269) 269
Book Chapter (85) 85
Trade Publication Article (26) 26
Book / eBook (22) 22
Transcript (18) 18
Publication (17) 17
Conference Proceeding (15) 15
Reference (13) 13
Dissertation (8) 8
Government Document (6) 6
Book Review (5) 5
Web Resource (5) 5
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28257) 28257
aspirin - therapeutic use (18784) 18784
aspirin (15977) 15977
female (14556) 14556
male (14491) 14491
middle aged (9907) 9907
aged (8970) 8970
platelet aggregation inhibitors - therapeutic use (8115) 8115
adult (6521) 6521
risk factors (5529) 5529
cardiac & cardiovascular systems (4192) 4192
treatment outcome (4102) 4102
animals (4026) 4026
aspirin - adverse effects (3976) 3976
prevention (3737) 3737
aspirin - administration & dosage (3692) 3692
drug therapy, combination (3617) 3617
anticoagulants - therapeutic use (3607) 3607
risk (3596) 3596
ticlopidine - analogs & derivatives (3476) 3476
clopidogrel (3446) 3446
pharmacology & pharmacy (3418) 3418
ticlopidine - therapeutic use (3225) 3225
medicine, general & internal (3222) 3222
stroke (2995) 2995
anti-inflammatory agents, non-steroidal - therapeutic use (2974) 2974
peripheral vascular disease (2759) 2759
aspirin - pharmacology (2673) 2673
aged, 80 and over (2586) 2586
time factors (2501) 2501
mortality (2347) 2347
therapy (2289) 2289
fibrinolytic agents - therapeutic use (2255) 2255
drug therapy (2244) 2244
low-dose aspirin (2231) 2231
care and treatment (2192) 2192
prospective studies (2105) 2105
hematology (2073) 2073
clinical trials as topic (2049) 2049
platelet aggregation inhibitors - adverse effects (2020) 2020
abridged index medicus (1996) 1996
thrombosis (1973) 1973
anticoagulants (1953) 1953
retrospective studies (1851) 1851
double-blind method (1843) 1843
follow-up studies (1819) 1819
surgery (1763) 1763
platelet aggregation inhibitors - administration & dosage (1755) 1755
nonsteroidal antiinflammatory drugs (1723) 1723
health aspects (1720) 1720
warfarin (1718) 1718
platelet aggregation - drug effects (1717) 1717
pregnancy (1711) 1711
analysis (1701) 1701
research (1699) 1699
cardiovascular disease (1687) 1687
stroke - prevention & control (1682) 1682
myocardial-infarction (1660) 1660
dose-response relationship, drug (1632) 1632
adolescent (1583) 1583
randomized controlled trials as topic (1567) 1567
medicine & public health (1564) 1564
warfarin - therapeutic use (1549) 1549
rats (1537) 1537
anti-inflammatory agents, non-steroidal - adverse effects (1516) 1516
heart attacks (1514) 1514
myocardial infarction - drug therapy (1503) 1503
heparin - therapeutic use (1490) 1490
risk assessment (1458) 1458
antiplatelet therapy (1443) 1443
clinical neurology (1411) 1411
disease (1406) 1406
patients (1373) 1373
recurrence (1360) 1360
acute coronary syndromes (1351) 1351
cardiology (1351) 1351
management (1337) 1337
blood platelets - drug effects (1305) 1305
cardiovascular diseases - prevention & control (1301) 1301
percutaneous coronary intervention (1266) 1266
inflammation (1254) 1254
secondary prevention (1243) 1243
stents (1238) 1238
dipyridamole - therapeutic use (1215) 1215
trial (1185) 1185
cardiovascular diseases (1184) 1184
dosage and administration (1178) 1178
blood platelets (1174) 1174
oncology (1152) 1152
hemorrhage - chemically induced (1149) 1149
prognosis (1124) 1124
studies (1118) 1118
inhibition (1115) 1115
platelet aggregation inhibitors - pharmacology (1114) 1114
clinical trials (1111) 1111
thrombosis - prevention & control (1109) 1109
cancer (1108) 1108
coronary heart disease (1099) 1099
child (1093) 1093
myocardial infarction - prevention & control (1085) 1085
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (12) 12
Online Resources - Online (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (31788) 31788
German (901) 901
French (726) 726
Russian (343) 343
Spanish (341) 341
Japanese (332) 332
Italian (306) 306
Chinese (152) 152
Dutch (96) 96
Polish (95) 95
Danish (57) 57
Portuguese (56) 56
Czech (33) 33
Norwegian (33) 33
Swedish (32) 32
Finnish (31) 31
Hungarian (30) 30
Hebrew (21) 21
Turkish (20) 20
Romanian (19) 19
Korean (18) 18
Ukrainian (17) 17
Serbian (15) 15
Croatian (14) 14
Bulgarian (12) 12
Slovak (9) 9
Lithuanian (8) 8
Bosnian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
European heart journal, ISSN 0195-668X, 2003, Volume 24, Issue 5, pp. 464 - 474
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | heart failure | risk factors | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | NATRIURETIC PEPTIDE | stroke | ASPIRIN | atrial fibrillation | CONVERTING-ENZYME INHIBITORS | THERAPY | WARFARIN | EJECTION FRACTION | ventricular ejection fraction | sinus rhythm | PERIPHERAL VASCULAR DISEASE | CANDESARTAN | THROMBOEMBOLISM | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | Biological Markers/blood | Natriuretic Peptide | Pyrimidines/ therapeutic use | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2019, Volume 2019, Issue 1, p. CD005431
Background Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile... 
Aspirin | Bed Rest | Bandages | Patient Positioning | Adrenal Cortex Hormones | Hyphema | Eye Injuries | Tranexamic Acid | Visual Acuity | Randomized Controlled Trials as Topic | Wounds, Nonpenetrating | Antifibrinolytic Agents | Mydriatics | Platelet Aggregation Inhibitors | Estrogens, Conjugated (USP) | Eyes & vision | Medicine General & Introductory Medical Sciences | Aminocaproic Acid | Adrenal Cortex Hormones [therapeutic use] | Aspirin [therapeutic use] | Humans | Platelet Aggregation Inhibitors [therapeutic use] | SECONDARY HEMORRHAGE | MEDICINE, GENERAL & INTERNAL | Patient Positioning [methods] | STREPTOKINASE | SICKLED ERYTHROCYTES | Hyphema [etiology; therapy] | GLAUCOMA | Estrogens, Conjugated ( USP) [therapeutic use] | TOPICAL AMINOCAPROIC ACID | RISK | Wounds, Nonpenetrating [complications] | CHILDREN | TRANEXAMIC ACID | Mydriatics [therapeutic use] | Aminocaproic Acid [therapeutic use] | OUTPATIENT MANAGEMENT | Antifibrinolytic Agents [therapeutic use] | UROKINASE | Antifibrinolytic Agents - therapeutic use | Wounds, Nonpenetrating - complications | Eye Injuries - complications | Tranexamic Acid - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Mydriatics - therapeutic use | Estrogens, Conjugated (USP) - therapeutic use | Patient Positioning - methods | Aminocaproic Acid - therapeutic use | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Child | Hyphema - therapy | Hyphema - etiology
Journal Article
PharmacoEconomics, ISSN 1170-7690, 7/2010, Volume 28, Issue 7, pp. 521 - 538
Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE... 
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Research-and-development | Tinzaparin-sodium, therapeutic use | Warfarin, therapeutic use | Dabigatran-etexilate, therapeutic use | Dalteparin-sodium, therapeutic use | Factor-Xa-inhibitors, therapeutic use | Antithrombotics, therapeutic use | Anticoagulants, therapeutic use | Deep-vein-thrombosis, Prevention | Enoxaparin-sodium, therapeutic use | Fondaparinux-sodium, therapeutic use | Rivaroxaban, therapeutic use | Low-molecular-weight-heparins, therapeutic use | Ardeparin-sodium, therapeutic use | Pulmonary-embolism, Prevention | Cost-effectiveness | REVISION HIP | PROLONGED ENOXAPARIN THERAPY | DEEP-VEIN THROMBOSIS | POSTOPERATIVE FONDAPARINUX | ANTITHROMBOTIC PROPHYLAXIS | DABIGATRAN ETEXILATE | MOLECULAR-WEIGHT HEPARIN | HEALTH CARE SCIENCES & SERVICES | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | ELECTIVE HIP | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ECONOMICS | Anticoagulants; therapeutic use; Antithrombotics; therapeutic use; Ardeparin-sodium; therapeutic use; Cost-effectiveness; Dabigatran-etexilate; therapeutic use; Dalteparin-sodium; therapeutic use; Deep-vein-thrombosis; Prevention; Enoxaparin-sodium; therapeutic use; Factor-Xa-inhibitors; therapeutic use; Fondaparinux-sodium; therapeutic use; Low-molecular-weight-heparins; therapeutic use; Pulmonary-embolism; Prevention; Research-and-development; Rivaroxaban; therapeutic use; Tinzaparin-sodium; therapeutic use; Warfarin; therapeutic use | Warfarin | Aspirin | Care and treatment | Thrombin | Cost benefit analysis | Pulmonary embolism | Orthopedic surgery | Angiogenesis inhibitors | Diagnosis | Salicylates | Thromboembolism | Health aspects | Medical care, Cost of | Studies | Anticoagulants | Literature | Joint replacement surgery | Thrombosis | Pharmaceuticals
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article